0210172210
0210172201
0210172205
ICNA0210172210EA
146
EUR
InStock
ICNA0210172210
ICNA0210172201
ICNA0210172205
5-Fluorouracile ∼99%, en poudre
5-Fluorouracile
5-Fluorouracil (5-FU) inhibits the activity of thymidylate synthetase, which affects pyrimidine synthesis and leads to depletion of intracellular TTP pools.
5-FU has also been proposed to interfere with the activity of ribosomal RNA binding protein (RRBP), at the level of pre-ribosomal RNA (pre-rRNA) processing. 5-Fluorouracil is a potent agent against solid tumors that was introduced in 1957 for clinical use. It remains one of the most effective chemotherapeutic agents in such conditions as colorectal cancer, even at its limited response rates (10 to 30%).
A potent antitumor agent that affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. It is metabolized to ribonucleotides and deoxyribonucleotides, which can be incorporated into RNA and DNA. Treatment of cells with 5-FU leads to an accumulation of cells in S-phase and has been shown to induce p53 dependent apoptosis.
Soluble in 1 M Ammonium Hydroxide (50 mg per ml), 1M NaOH and DMSO (10 to 50 mg/ml)/DMF.
Attention: Research Use Only (RUO).